#BDRX hashtag - Bluesky

#BDRX Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

www.stocktitan.net/news/BDRX/biodexa-launch...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

ADR Ratio Change Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an ADR ratio change from 1 ADR = 100,000 ordinary shares to 1 ADR = 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders must surrender five old ADRs for one new ADR (New CUSIP: 59564R872).The change will operate as a one-for-five reverse ADR split for ADRs only; ordinary shares are not affected. The depositary, JP Morgan Chase Bank, N.A., will manage exchanges and sell any aggregate fractional interests, distributing net proceeds. The Company said the change aims to comply with Nasdaq's $1.00 minimum bid requirement but gave no assurance it will achieve that outcome.

#BDRX ADR Ratio Change

www.stocktitan.net/news/BDRX/adr-ratio-irqj...

0 0 0 0

StockTitan

@stocktitan.net

3 weeks ago

Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an initial financial grant supporting the launch of Life's a Polyp Foundation, the first U.S. patient advocacy group focused exclusively on Familial Adenomatous Polyposis (FAP).Biodexa highlighted its lead program eRapa, an encapsulated rapamycin in the registrational Phase 3 Serenta trial with >20% enrollment and FDA Fast Track designation, and said the grant aims to boost patient resources, community support, and awareness for FAP patients and families.

#BDRX Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Trade Alerts, Thursday December 18, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Thu Dec 18th - #OCC #JZXN #VMAR #RVYL #PYXS #HOWL #GANX #EVTV #BDRX #AZI #ATON #PSQH #$NMG - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Biodexa Announces Pricing of $10 Million Public Offering December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today

#BDRX Biodexa Announces Pricing of $10 Million Public Offering

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa (Nasdaq: BDRX) announced enrolment of the first three European patients into the pivotal Phase 3 Serenta trial of eRapa for familial adenomatous polyposis (FAP) at the University of Bonn, Germany on December 1, 2025. The Serenta trial (NCT06950385) is a double‑blind, placebo‑controlled study of 168 patients randomized 2:1 to evaluate eRapa safety and efficacy.All sites are identified and onboarding; nine additional European sites across the Netherlands, Spain, Denmark, and Italy are expected to activate in the next 2–3 months. The trial began US enrolment in August 2025 and is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.

#BDRX Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa (Nasdaq: BDRX) activated the University of Bonn as the first European site for the registrational Phase 3 Serenta trial evaluating eRapa in familial adenomatous polyposis (FAP) on November 24, 2025.The company said this follows approval of its Clinical Trial Application by the European Medicines Agency and cites collaborators Emtora Biosciences, CRO Precision for Medicine, and a $20 million grant from the Cancer Prevention and Research Institute of Texas. The randomized, double-blind, placebo-controlled Serenta trial (NCT06950385) began US enrollment in August 2025. Nine additional European sites across the Netherlands, Spain, Denmark, and Italy are expected to activate in the next 2–3 months. For eligibility and site details visit https://serentatrial.com/.

#BDRX Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

www.stocktitan.net/news/BDRX/biodexa-activa...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals (NASDAQ:BDRX) reported interim results for H1 2025, highlighting significant progress in its clinical pipeline. The company's lead candidate eRapa entered Phase 3 trials for FAP with first patient enrollment in Puerto Rico, while securing Orphan Drug Designation in Europe. The company also initiated a Phase 2a study of tolimidone in Type 1 Diabetes.Financial highlights include a $35 million Equity Line of Credit with C/M Capital Master Fund LP, and a $3 million grant awarded to collaboration partner Emtora Biosciences. R&D costs decreased to £1.67 million (from £2.19M in 1H24), while cash balance stood at £4.04 million as of June 30, 2025. [ "Secured $35 million Equity Line of Credit facility", "Collaboration partner received additional $3 million grant, bringing total non-dilutive funding to $20 million", "R&D costs decreased by 24% to £1.67 million", "Successfully advanced eRapa to Phase 3 trials with first patient enrollment", "Obtained European Orphan Drug Designation for eRapa in FAP" ]

#BDRX Interim results for the six months ended June 30, 2025

www.stocktitan.net/news/BDRX/interim-result...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease Biodexa launches Phase 3 trial of eRapa for FAP treatment, backed by $20M CPRIT grant. Phase 2 showed 29% polyp reduction. Fast Track and Orphan Drug status secured for $7.3B market opportunity.

#BDRX Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

www.stocktitan.net/news/BDRX/biodexa-moves-...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the enrollment of its first two patients in the pivotal Phase 3 Serenta trial for eRapa, targeting Familial Adenomatous Polyposis (FAP). The trial will be conducted across 30 sites (20 in US, 10 in Europe) and will evaluate 168 patients in a 2:1 drug/placebo randomized study.The company aims to develop the first non-surgical treatment for FAP, a hereditary condition that typically leads to colorectal cancer if untreated. The program has received $20 million in grant funding from CPRIT and targets a $7.3 billion addressable market. The trial follows promising Phase 2 results and represents a potential breakthrough in FAP treatment, where currently only surgical resection is available.

#BDRX Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active Biodexa's ADR ratio shifts from 1:10,000 to 1:100,000 ordinary shares, effectively executing a 1:10 reverse ADR split. See impact on holdings.

#BDRX ADR Ratio Change Effective

www.stocktitan.net/news/BDRX/adr-ratio-chan...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market First non-surgical FAP treatment advances with FDA Fast Track status. Phase 3 trial launches across US/EU sites. See how Biodexa aims to capture $7B market opportunity.

#BDRX How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

www.stocktitan.net/news/BDRX/how-biodexa-is...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

ADR Ratio Change Biodexa Pharmaceuticals (NASDAQ: BDRX) has announced a significant change in its American Depositary Receipts (ADR) ratio. The company will modify its ADR ratio from 1:10,000 (1 ADR representing 10,000 ordinary shares) to 1:100,000 (1 ADR representing 100,000 ordinary shares), effective July 31, 2025.ADR holders will be required to exchange their existing ADRs at a ratio of 10:1, with JP Morgan Chase Bank managing the exchange process. This change will effectively function as a 1-for-10 reverse ADR split, though the company's ordinary shares will remain unaffected. The primary goal is to achieve compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

#BDRX ADR Ratio Change

www.stocktitan.net/news/BDRX/adr-ratio-einq...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon Jul 14th - #ISSC #WINT #VBTX #TROO #SNDL #RANI #PFIS #MCRB #IOBT #EPIX #CALC #BDRX #ACHV #ODV #KODK #KNOP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals (NASDAQ:BDRX) has filed a Clinical Trial Application (CTA) with the European Medicines Agency for its Phase 3 Serenta trial investigating eRapa in Familial Adenomatous Polyposis (FAP). The trial will initially cover clinical sites in Denmark, Germany, Netherlands, and Spain, with Italy to be added later.The company has achieved several milestones for its eRapa program, including FDA Fast Track Designation, European Orphan Drug designation, and initiation of its first US clinical site. The program is supported by a $20 million grant from CPRIT. The Serenta trial (NCT06950385) is designed as a randomized, double-blind, placebo-controlled Phase 3 study, with European sites expected to begin enrollment in Q4 2025.

#BDRX Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM Latest shareholder meeting sees unanimous approval of all proposed resolutions. View complete voting results and strategic implications for Biodexa's future. Get Details

#BDRX Results of Annual General Meeting

www.stocktitan.net/news/BDRX/results-of-ann...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment First US site opens for Serenta Phase 3 trial targeting FAP treatment. Backed by $20M grant, trial follows Fast Track Designation. See enrollment details.

#BDRX Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients Biodexa launches dedicated website for Phase 3 Serenta trial in Familial Adenomatous Polyposis. Learn about trial participation and latest developments.

#BDRX Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

www.stocktitan.net/news/BDRX/biodexa-unveil...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Wed Jun 18th - #TMC #RELI #PRTH #OMEX #MRIN #LGHL #HSDT #GALT #FLL #ZENV #SONN #CCLD #BDRX #APVO #RHC #MTR #NINE #HUYA #GHLD #WHLR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

News; ( NASDAQ: #BDRX ) Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study Biodexa Pharmaceuticals (NASDAQ:BDRX) has enrolled its first patient in a Phase 2a trial for Tolimidone, a potential treatment for type 1 diabetes. Originally discovered by Pfizer for gastric ulcers, Tolimidone is being repurposed as it activates the Lyn kinase enzyme, which could help the body produce insulin. The Phase 2a dose confirmation study, conducted with the University of Alberta, will measure C-peptide and HbA1c levels across 12 patients in three dose groups over three months. Preclinical studies at the University of Alberta showed promising results, including beta cell proliferation in human cadaver samples. The global type 1 diabetes treatment market, currently valued at $16.97 billion, is projected to reach $26.22 billion by 2032, growing at a 6.9% CAGR.

#BDRX Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

www.stocktitan.net/news/BDRX/biodexa-hits-k...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

PRISM Mid-Day Movers:
Houston American Energy ( #HUSA) surged 89.31%
DigitalTurbine ( #APPS) jumped 54.68%
Other PRISM Movers:
• #GalectinGALT ( #GALT) +62.36%
• #Sunrun ( #RUN) -42.21%
• #AdialPharma ( #ADIL) -27.71%
• #biodexa_pharma ( #BDRX) -20.89%
prismmarketview.com/prism-mid-da...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority Key resolutions passed include share nominal value reduction and new director allotment powers. See how these changes impact Biodexa's corporate structure. Get Details.

#BDRX Result of General Meeting

www.stocktitan.net/news/BDRX/result-of-gene...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells New Phase 2 study explores Tolimidone's potential to regenerate insulin-producing cells in Type 1 Diabetes patients. See breakthrough trial details.

#BDRX Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

www.stocktitan.net/news/BDRX/biodexa-announ...

0 0 0 0